RAD April 2022 Conference Abstracts and Posters
197 - Patients who feel more accountable have better adherence: a clinical study in patients with xerosis in the context of previous or current atopic dermatitis
Madison K. Cook BS, Katherine A. Kelly BS, Patrick O. Perche BS, Rohan Singh BS, Esther A. Balogh MD, Irma Richardson MHA, Steven R. Feldman MD PhD
201 - Identification of meaningful aspects of health connected to the symptom of nocturnal scratching in patients with atopic dermatitis
Lucia Cesnakova, MS; Keith Meadows, BA, PhD; Stefan Avey, PhD; Judy Barrett, MSc, DipM; Meenakshi Chatterjee, PhD; Ieuan Clay, PhD; Jennifer Goldsack, MChem, MA, MBA; Sandra Goss, PhD; Katelyn R. Keyloun, PharmD, MS; Carrie Northcott, PhD; Francesco Patalano, MD; Doina Sirbu; Wendy Smith Begolka, MBS; Nadia Thyssen; Sylvain Zorman
202 - Mixed Method Analyses to Document Content Validity of Sleep Disturbance Measurements in Adult and Adolescent Populations with Moderate-to-Severe Atopic Dermatitis
Jorge Puelles, Anna Ryzhkova, Sylvie Gabriel, Danielle Rodriguez, Fatoumata Fofana, Carla Dias-Barbosa
203 - A Phase 2a study of amlitelimab, a novel non-depleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD)
Weidinger S, Cork M, Reich A, Bieber T, Gilbert S, Brennan N, Wilson R, Quaratino S and Porter-Brown B on behalf of the KY1005-CT02 study team
204 -Post-hoc Analyses of Lebrikizumab Phase 3 Trials (LAVOLTA I and II): Enhanced Efficacy in Patients with Prior Exacerbations and Elevated Baseline FENO or Blood Eosinophilia
Ellen Sher, Phillip Korenblat, Guy Brusselle, Stanley Fineman, Ralph Zitnik, Luna Sun, Ram Gopalan, Jonathan Corren
205 - Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials
Jonathan I. Silverberg, Diamant Thaçi, Julien Seneschal, Linda Stein Gold, Andrew Blauvelt, Eric Simpson, Chia-Yu Chu, Zhuqing T. Liu, Renata Gontijo Lima, Sreekumar Pillai, Emma Guttman-Yassky
206 - Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis
Evgeny Berdyshev, Elena Goleva, Robert Bissonnette, Marco Ramirez-Gama, Patricia Taylor, Gabriel Bologna, Amy Praestgaard, Mark Boguniewicz, Sivan Hare, Noah A. Levit, Ana B. Rossi, Annie Zhang, Donald Y.M. Leung
207 - Improvement in Disease Severity and Quality of Life in Patients With Atopic Dermatitis Treated With Dupilumab for up to 18 Months: Real-World Data From the PROSE Registry
Jerry Bagel, Gil Yosipovitch, David M. Pariser, Robert Y. Lin, Haixin Zhang, Zafer E. Ozturk, Andrew Korotzer
208 - Atopic Dermatitis in a Pediatric Population can be Associated with a Negative Impact on Families that Increases with Disease Severity
Eric L. Simpson, Jonathan I. Silverberg, Stephan Weidinger, Sebastien Barbarot, Ashish Bansal, Lysel Brignoli, Ryan B. Thomas, Chien-Chia Chuang, Ana B. Rossi
209 - Dupilumab Treatment Reduces Skin Pain in Infants and Young Children with Moderate-to-Severe Atopic Dermatitis Aged 6 Months to 5 Years
Amy S. Paller, Jonathan I. Silverberg, Elaine C. Siegfried, Mercedes E. Gonzalez, Lynda C. Schneider, Robert Sidbury, Haixin Zhang, Randy Prescilla, Zhixiao Wang